All In Biotech

Investigational drug · Phase 3

Recombinant Human Prourokinase

Also called: rhPro-UK

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke AIS.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

12

Any phase or sponsor naming "Recombinant Human Prourokinase"

First trial start

2026

Nov 30, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Recombinant Human Prourokinase", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acute Ischemic Stroke AIS

Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Recombinant Human Prourokinase" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 50 on PubMed

Also in development for Acute Ischemic Stroke AIS

  • hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials

    Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)

  • SIM0811Phase 31 trial

    Jiangsu Simcere Pharmaceutical Co., Ltd. · Acute Ischemic Stroke AIS

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.